Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | nuclear factor, erythroid 2-like 2 | Starlite/ChEMBL | No references |
Homo sapiens | flap structure-specific endonuclease 1 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Trypanosoma brucei | exonuclease, putative | flap structure-specific endonuclease 1 | 380 aa | 322 aa | 24.5 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Entamoeba histolytica | hypothetical protein | 0.0043 | 1 | 1 |
Trichomonas vaginalis | flap endonuclease-1, putative | 0.0031 | 0.6762 | 1 |
Schistosoma mansoni | transcription factor LCR-F1 | 0.0043 | 1 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 1 | 1 |
Echinococcus granulosus | flap endonuclease 1 | 0.0031 | 0.6762 | 0.6762 |
Loa Loa (eye worm) | flap endonuclease-1 | 0.0031 | 0.6762 | 1 |
Trypanosoma brucei | flap endonuclease-1 (FEN-1), putative | 0.0031 | 0.6762 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 1 | 1 |
Plasmodium falciparum | flap endonuclease 1 | 0.0031 | 0.6762 | 1 |
Echinococcus multilocularis | flap endonuclease 1 | 0.0031 | 0.6762 | 0.6762 |
Trypanosoma cruzi | flap endonuclease-1 (FEN-1), putative | 0.0031 | 0.6762 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0043 | 1 | 1 |
Giardia lamblia | Flap structure-specific endonuclease | 0.0031 | 0.6762 | 1 |
Echinococcus granulosus | Basic leucine zipper bZIP transcription | 0.0043 | 1 | 1 |
Leishmania major | flap endonuclease-1 (FEN-1), putative | 0.0031 | 0.6762 | 1 |
Brugia malayi | Flap endonuclease-1 | 0.0031 | 0.6762 | 0.6762 |
Echinococcus multilocularis | Basic leucine zipper (bZIP) transcription | 0.0043 | 1 | 1 |
Toxoplasma gondii | flap structure-specific endonuclease 1, putative | 0.0031 | 0.6762 | 1 |
Entamoeba histolytica | Flap nuclease, putative | 0.0031 | 0.6762 | 0.6762 |
Plasmodium vivax | flap endonuclease 1, putative | 0.0031 | 0.6762 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 1 | 1 |
Schistosoma mansoni | flap endonuclease-1 | 0.0028 | 0.5947 | 0.5947 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 1.4125 uM | PUBCHEM_BIOASSAY: qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1). (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488813] | ChEMBL. | No reference |
Potency (functional) | 16.3601 uM | PUBCHEM_BIOASSAY: Nrf2 qHTS screen for inhibitors. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493153, AID493163, AID504648] | ChEMBL. | No reference |
Potency (functional) | 18.526 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 29.081 uM | PUBCHEM_BIOASSAY: qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493107, AID493125] | ChEMBL. | No reference |
Potency (functional) | = 35.4813 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Human Jumonji Domain Containing 2E (JMJD2E). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 56.2341 uM | PubChem BioAssay. qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 100 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.